Introduction to Pemazyre (Pemigatinib) 13.5mg 

Pemitinib (Pemigatinib)13.5mg is a targeted prescription medicine used for the treatment of certain advanced cancers, particularly cancers involving fibroblast growth factor receptor (FGFR) gene alterations. This medicine belongs to a specialized group of oncology drugs known as targeted cancer therapies that work by blocking specific proteins responsible for cancer cell growth.

Pemitinib (Pemigatinib)13.5mg is classified under Prescription Medicines, Oncology Medicines, Anticancer Drugs, and Oral Cancer Therapies. It contains Pemigatinib, which works by inhibiting abnormal FGFR signaling pathways that promote the growth and spread of cancer cells.

The original brand of Pemigatinib is Pemazyre, which contains the same active ingredient Pemigatinib and is widely used in oncology treatment when prescribed by a qualified healthcare professional.

What Is Pemazyre (Pemigatinib)? 

Pemazyre is the brand name for Pemigatinib, an oral targeted therapy used for the treatment of cancers associated with fibroblast growth factor receptor (FGFR) abnormalities.

Pemigatinib belongs to a class of medicines known as FGFR inhibitors. These medicines work by blocking the activity of abnormal FGFR proteins that help cancer cells grow and spread.

Generic versions such as Pemitinib 13.5mg contain the same active compound Pemigatinib and may be used depending on physician recommendation and regional availability.

Drug Class and Mechanism of Action 

Pemigatinib is classified as an FGFR inhibitor and targeted anticancer agent with strong antineoplastic properties.

How Pemigatinib Works 

It works in several ways:

• Blocks fibroblast growth factor receptor (FGFR1, FGFR2, and FGFR3) signaling pathways

• Prevents cancer cells from receiving growth signals

• Slows tumor cell proliferation

• Helps control the spread of cancer cells

Through these mechanisms, Pemigatinib helps slow or stop the progression of cancers driven by FGFR gene alterations.

How Pemazyre Works in the Body 

Certain cancers grow due to abnormal FGFR gene signaling. Pemazyre helps block these abnormal signals, preventing cancer cells from multiplying and spreading.

Key Actions of Pemigatinib 

• Inhibiting abnormal FGFR protein activity

• Interrupting cancer cell growth signals

• Reducing tumor progression

• Helping control cancer development

Some generic versions such as Pemitinib deliver the same active compound, allowing similar targeted cancer therapy when prescribed appropriately.

Medical Uses of Pemazyre (Pemigatinib) 13.5mg 

Pemazyre 13.5mg is prescribed for specific cancers with fibroblast growth factor receptor abnormalities.

Pemazyre for Cholangiocarcinoma 

Pemazyre is commonly used for patients with cholangiocarcinoma (bile duct cancer) that has FGFR2 gene fusion or rearrangement and has progressed after previous treatment.

Potential Benefits 

• Helps slow tumor growth

• Provides targeted therapy for FGFR-altered cancers

• Helps control disease progression in advanced bile duct cancer

Generic alternatives like Pemitinib 13.5mg may also be prescribed under medical supervision when Pemigatinib therapy is recommended.

Who Can Take Pemitinib 13.5mg? 

Because Pemigatinib is a potent oncology medicine, treatment should always be supervised by an experienced healthcare provider.

Eligibility Criteria 

Patients may be prescribed Pemazyre if they:

• Have cholangiocarcinoma with FGFR2 fusion or rearrangement

• Have previously received systemic cancer therapy

• Are suitable candidates for targeted FGFR inhibitor treatment

Certain generic options such as Pemitinib may also be considered depending on availability and physician decision.

Who Should Avoid Pemazyre (Pemigatinib) 13.5mg 

Pemazyre should NOT be used by:

• Pregnant women or women planning pregnancy

• Individuals with hypersensitivity to Pemigatinib

• Patients with severe uncontrolled liver or kidney disease unless monitored by a specialist

Pemazyre (Pemigatinib) 13.5mg Dosage and Administration 

Standard Dosage Guidelines 

Typical dosage recommendations include:

• Pemigatinib13.5mg once daily

• Usually taken for 14 days followed by 7 days off in a 21-day treatment cycle

• Tablets should be swallowed whole

• Can be taken with or without food

Dosage Adjustments 

Doctors may adjust the dose depending on:

• Liver function

• Blood phosphate levels

• Side effects such as hyperphosphatemia

• Individual treatment response

Side Effects of Pemazyre 13.5mg 

Like all cancer medicines, Pemazyre may cause side effects.

Common Side Effects 

• Fatigue and weakness

• Mouth sores (stomatitis)

• Dry mouth

• Hair thinning or hair loss

• Diarrhea or constipation

• Nail or skin changes

Serious Side Effects 

• Hyperphosphatemia (high phosphate levels in blood)

• Eye problems including retinal disorders

• Liver enzyme abnormalities

• Severe gastrointestinal symptoms

Patients should report any unusual symptoms to their doctor immediately.

Storage:
Store below 25°C in a cool, dry place, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.

Frequently Asked Questions (FAQs) 

1. Is Pemazyre (Pemigatinib)13.5mg chemotherapy? 

No. Pemazyre is a targeted cancer therapy that works by blocking FGFR signaling pathways involved in tumor growth.

2. What cancer is Pemigatinib used for? 

Pemigatinib is primarily used to treat cholangiocarcinoma (bile duct cancer) with FGFR2 gene fusion or rearrangement.

3. Can Pemazyre be used long-term? 

Yes. Some patients may continue treatment as long as the medicine remains effective and side effects are manageable.

4. Why are blood tests required during treatment? 

Doctors monitor phosphate levels, liver function, and other parameters to ensure the medicine is working safely.

5. Can pregnant women take Pemitinib13.5mg? 

No. Pemigatinib may cause harm to an unborn baby and should not be used during pregnancy.

6. Is Pemitinib13.5mg the same as Pemazyre? 

Pemitinib contains Pemigatinib, the same active ingredient found in Pemazyre. Generic versions may be available depending on region.

7. Do I need a prescription to buy Pemitinib (Pemigatinib)13.5mg? 

Yes. Pemitinib13.5mg is a prescription-only medicine and must be used under the supervision of a qualified healthcare professional.

Medical Disclaimer 

Disclaimer:
The information provided on this page is for educational and informational purposes only and should not be considered medical advice. Pemazyre (Pemigatinib) is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. Always consult your physician before starting, stopping, or changing any medication.